1 Accuracy of digital chest x-ray analysis with artificial intelligence software as a triage and screening 2 tool in hospitalized patients being evaluated for tuberculosis in Lima, Peru. 3 Amanda Biewer^{1*}, Christine Tzelios^{2*}, Karen Tintaya³, Betsabe Roman³, Shelley Hurwitz², Courtney 4 5 Yuen⁴, Carole D. Mitnick⁴, Edward Nardell⁴, Leonid Lecca³, Dylan B. Tierney^{4,5}, Ruvandhi R. 6 Nathavitharana1 7 8 ¹ Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 9 ² Harvard Medical School, Boston, MA 10 ³ Socios en Salud, Lima, Peru 11 ⁴ Brigham and Women's Hospital and Harvard Medical School, Boston, MA 12 ⁵ Massachusetts Department of Public Health, Boston, MA 13 * contributed equally 14 15 Abstract 16 Introduction: 17 Tuberculosis (TB) transmission in healthcare facilities is common in high-incidence countries. Yet, the 18 optimal approach for identifying inpatients who may have TB is unclear. We evaluated the diagnostic 19 accuracy of gXR (Qure.ai, India) computer-aided detection (CAD) software versions 3 and 4 (v3 and 20 v4) as a triage and screening tool within the FAST (Find cases Actively, Separate safely, and Treat 21 effectively) transmission control strategy. 22 23 Methods: 24 We prospectively enrolled two cohorts of patients admitted to a tertiary hospital in Lima, Peru: one 25 group had cough or TB risk factors (triage) and the other did not report cough or TB risk factors (screening). We evaluated the sensitivity and specificity of qXR for the diagnosis of pulmonary TB 26 27 using culture and Xpert as primary and secondary reference standards, including stratified analyses 28 based on risk factors.

Results: In the triage cohort (n=387), qXRv4 sensitivity was 0.95 (62/65, 95% CI 0.87-0.99) and specificity was 0.36 (116/322, 95% CI 0.31-0.42) using culture as reference standard. There was no difference in the area under the receiver-operating-characteristic curve (AUC) between qXRv3 and qxRv4 with either a culture or Xpert reference standard. In the screening cohort (n=191), only one patient had a positive Xpert result, but specificity in this cohort was high (>90%). qXR sensitivity did not differ stratified by sex, age, prior TB, HIV, and symptoms. Specificity was higher in people without prior TB and people with a cough for <2 weeks. Conclusions: qXR had high sensitivity but low specificity as a triage in hospitalized patients with cough or TB risk factors. Screening patients without cough in this setting had a low diagnostic yield. These findings further support the need for population and setting-specific thresholds for CAD programs.

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Diagnosis remains the largest gap in the tuberculosis (TB) cascade of care. In 2021, of the 10.6 million people estimated to become sick due to TB, only 6.4 million were diagnosed and notified to national notification systems¹. Efforts to increase and accelerate diagnoses are critical to prevent severe disease, avert TB deaths, and halt ongoing transmission². Healthcare facilities are known hotspots for TB transmission in high-incidence settings^{3–7}. Globally, the rate of TB disease among healthcare workers is estimated to be at least double that of the general adult population, suggesting significant transmission in health facilities^{8,9}. The FAST (Find cases Actively, Separate safely, and Treat effectively) strategy was developed to reduce TB transmission in healthcare settings, based on the principle that most transmission occurs from patients with unsuspected and thus undiagnosed TB, including drug-resistant strains¹⁰. FAST relies on identifying potentially infectious patients, typically with cough screening, followed by rapid sputum-based molecular tests that include first line resistance testing to enable prompt initiation of effective treatment^{7,10}.(1, 2) FAST has been implemented in a variety of settings, including Peru, Bangladesh, Russia, and Vietnam¹¹⁻¹⁴. Given the slow scale up of rapid molecular tests¹, due to barriers such as cost, optimizing screening approaches for the FAST strategy is critical for its implementation success. Triage is the process of making clinical decisions based on symptoms, signs, risk factors, or test results¹⁵. Rapid and accurate triage tests play an important role in identifying patients requiring further diagnostic evaluation among those with symptoms or risk factors for disease¹⁶. Screening similarly involves non-diagnostic testing to distinguish between people who likely have the disease from those who are unlikely to have the disease, typically in a population who do not have symptoms¹⁵. There is a long history of using chest radiography (CXR) to screen for pulmonary TB, but

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

its utility in high TB incidence settings has been limited by the scarcity of skilled radiologists to interpret images. 17 The advent of digital radiography coupled with computer aided detection (CAD) software eliminates this potential barrier, making it more feasible to implement CXR for triage or screening in resource limited settings. CAD uses artificial intelligence algorithms to analyze radiographs for abnormalities consistent with TB. CAD is now recommended by the World Health Organization (WHO) as an alternative to human readers¹⁷. Nonetheless, while CAD sensitivity for both triage and screening is typically >90%, CAD specificity varies widely, from 23%-66% for screening 18-20 and 25%–79% for triage^{18,21,22} when compared to a microbiological reference standard. Questions remain regarding the optimal approach for using CAD to identify potentially infectious people with TB, particularly in hospital settings. A retrospective case-control study evaluating CAD in patients presenting with respiratory symptoms to a tertiary care hospital in India demonstrated moderate sensitivity and specificity (71% and 80% respectively) for the detection of pulmonary TB²³. However, TB prevalence surveys reveal a high proportion of people diagnosed with pulmonary TB who do not report symptoms,²⁵ highlighting poor implementation and yield of symptom screening²⁴. Moreover, many CAD studies have focused on triage of outpatients presenting with symptoms^{26–29}; although there are some examples of CAD screening programs that are not contingent on symptom screening, these have been community-based^{30–33}. The aim of this study was to evaluate the diagnostic accuracy of digital CXR with CAD software as a tool for: 1) triage—among patients with cough or TB risk factors—and; 2) screening—among patients without cough or TB risk factors—to identify admitted patients who should undergo molecular TB testing in a tertiary care hospital in Lima, Peru.

Methods

Study design and participants

We conducted a cross-sectional diagnostic accuracy study that was embedded in a larger prospective study evaluating FAST implementation at Hospital Nacional Hipolito Unanue (HNHU), a 700-bed public, tertiary-care referral hospital in Lima, Peru (https://clinicaltrials.gov/ct2/show/NCT02355223). Patients admitted to HNHU from January 2nd 2018 to December 31st 2019 were consecutively screened by the FAST implementation team study staff using a standardized questionnaire upon facility admission, as previously described¹¹¹. Two cohorts were enrolled for this diagnostic accuracy sub-study. Eligible individuals were adults (≥ 18 years old) who, (upon questioning by the study team), reported either: 1) cough of any duration and/or the following risk factors for TB: contact with someone diagnosed with pulmonary TB, a current active TB diagnosis, or a history of prior active TB (triage cohort); or 2) no cough or TB risk factors (screening cohort).

Ethics statement

The study was approved by the Institutional Review Boards of HNHU and Brigham and Women's Hospital. Written informed consent was obtained from all patients. Participants were assigned a unique study ID number, recorded on data collection forms and clinical specimens to facilitate data linkage; names and other obvious identifiers were not used on data collection forms, thus authors did not have access to information that could identify individual participants during or after data collection.

Study procedures, data collection, and outcome classification

On the day of admission, patients in both cohorts who were admitted through the emergency room underwent posterior-anterior digital CXR and study staff collected at least 2 sputum samples for TB testing using smear microscopy, mycobacterial culture, Xpert MTB/RIF (Xpert, Cepheid, Sunnyvale, CA), and/or GenoType MTBDRplus line probe assay. De-identified CXR images were electronically transferred for automated analysis (blinded to other demographic and clinical data including the results of other TB testing) by the developers of qXR (qure.ai, Mumbai, India) who ran versions 3.0 (v3) and 4.0 (v4) on all images. CXR was obtained prospectively but qXR results were not used to guide clinical management. Information on socio-demographic and clinical variables including current and prior TB history, co-morbidities, and microbiological test results, was collected at the time of enrollment, or retrieved from the medical records using standardized case report forms. Culture and Xpert results were classified separately as binary variables (positive or negative for *Mycobacterium tuberculosis*). If a patient had more than one culture result and at least one or more were positive, the binary result was classified as positive; the same applied to Xpert results.

Analyses

For our primary diagnostic accuracy analyses, the diagnosis of pulmonary TB in both the triage and screening cohorts was established by the presence of a sputum culture that grew *Mycobacterium tuberculosis*. For our secondary diagnostic accuracy analyses, the diagnosis of pulmonary TB in both the triage and screening cohorts was established by the presence of a positive sputum Xpert result. Analyses using qXRv4 are presented in the main manuscript and qXRv3 are presented in the supplementary data. qXR sensitivity and specificity (with exact 95% C.I.s) for pulmonary TB were calculated using the manufacturer's prespecified thresholds (0.5 for v3 and 0.65 for v4) per STARD guidelines (see supplementary files)³⁴. DeLong's non-parametric method was applied to compare

differences between the areas under the receiver operating characteristic curve (AUC) for the two qXR software versions. We also estimated the specificity at the threshold score at which sensitivity was closest to 90% (WHO triage test minimum TPP recommended criteria)³⁵. Pre-specified sensitivity analyses were designed to examine qXR accuracy when certain groups known to have increased risk for TB were excluded: people with HIV, people with prior TB, and people with other respiratory diseases (asthma or bronchiectasis).

Using Fisher's exact test, we assessed performance differences in prespecified groups with characteristics or risk factors that may impact diagnostic test performance: male sex, older age, prior TB, HIV co-infection, other respiratory disease co-morbidities, presence of TB symptoms in WHO symptom screen (cough, fever, night sweats, weight loss), and higher-grade sputum smear result.

Analyses were completed using STATA/IC version 16 (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.).

Results

During the study period we enrolled 964 patients admitted to HNHU who had cough or TB risk factors, of whom 489 underwent digital CXR in the triage cohort (Figure 1). Participants who were taking anti-TB drugs or had taken them within one year of enrollment (n=50; 10%) were excluded as were those who had no microbiological testing (n=20; 4%). We enrolled 220 individuals without cough or TB risk factors in the screening cohort. Screening participants who were household contacts of people who experienced TB were excluded (n=27; 13%) as were those who had no microbiological testing (n=9; 4%).

Figure 1: Study Flow Diagram

Triage cohort

Demographics

Of the 419 participants in the triage cohort, 387 (93%) had a mycobacterial culture result; it was positive in 65 (17%) participants, of whom 41 (63%) also had positive sputum-smear microscopy results. In this cohort, 398 (95%) had an Xpert MTB/RIF result; it was positive in 69 (17%), of whom 39 (57%) had positive smear microscopy. Culture and Xpert results were largely concordant, although Xpert was positive in some people who did not have culture or who had a negative culture (Table S1). Compared to participants without TB (based on sputum culture results), participants with culture confirmed TB were more likely to be younger, male, have a history of incarceration, report cough longer than 2 weeks, fever, or weight loss, and not have a history of any respiratory diseases or a prior history of TB (Table 1).

Table 1: Demographic and clinical characteristics of enrolled participants

		Triage Patients				Screening* Patients	
	Overall (n=419)	TB^	No TB	No Culture	P-	Overall	P-
		(n=65)	(n=322)	Performed	value**	(n=184)	value**
				(n=32)			
Median Age (years,	41.35 (26.8, 56.6)	35.34	42.01	44.68 (31.7,	0.003	36.19 (25.19,	0.015
interquartile range)		(24.0,	(27.5,	63.3)		50.53)	
		48.6)	57.0)				
Sex, No (%)							
Female	164 (39.1)	17 (26.1)	134 (41.6)	13 (40.6)	0.025	111 (60.3)	<0.001
Male	255 (60.9)	48 (73.9)	188 (58.4)	19 (59.4)		73 (39.7)	
History of Previous TB,							
No (%)							
Yes	140 (33.4)	13 (20.0)	114 (35.4)	13 (40.6)	0.014	0 (0.00)	<0.001
No	278 (66.4)	52 (80.0)	207 (64.3)	19 (59.4)		184 (100)	
Refused	1 (0.20)	0 (0.00)	1 (0.3)	0 (0.00)			
HIV, No (%)							
Yes	36 (8.6)	7 (10.8)	28 (8.7)	1 (3.1)	0.635	1 (0.5)	<0.001
No	383 (91.4)	58 (89.2)	294 (91.3)	31 (96.9)		183 (99.5)	

Smoking, No (%)							
Never	202 (48.2)	28 (43.0)	162 (50.3)	12 (37.5)	0.501	99 (53.8)	0.637
Former	161 (38.4)	30 (46.2)	116 (36.0)	15 (46.9)	0.002	51 (27.7)	0.007
Current	56 (13.4)	7 (10.8)	44 (13.7)	5 (15.6)		34 (18.5)	
Alcohol, No (%)							
Never	107 (25.5)	9 (13.9)	90 (28.0)	8 (25.0)	0.092	32 (17.3)	<0.001
Former	121 (28.9)	22 (33.9)	90 (28.0)	9 (28.1)		33 (18.0)	
Current	189 (45.1)	32 (49.2)	142 (44.0)	15 (46.9)		119 (64.7)	
Missing	2 (0.5)	2 (3.0)	0 (0.00)	0 (0.00)		0 (0.00)	
Respiratory Disease, No			,	, ,		, ,	
(%)							
Asthma	28 (6.7)	1 (1.5)	26 (8.1)	2 (6.3)	0.047	2 (1.1)	0.001
Bronchiectasis	13 (3.1)	0 (0.00)	11 (3.4)	1 (3.1)		182 (98.9)	
None	378 (90.2)	64 (98.5)	285 (88.5)	29 (90.6)		0 (0.00)	
Diabetes, Type II, No	, ,	, ,	, ,	,		, ,	
(%)							
Yes	58 (13.8)	9 (13.9)	42 (13.0)	7 (21.9)	0.842	25 (13.6)	1.000
No	361 (86.2)	56 (86.1)	280 (87.0)	25 (78.1)		159 (86.4)	
Prison, No (%)		30 (00.2)	200 (07.0)	25 (7 5.2)		100 (00.1)	
Yes	62 (14.8)	16 (24.6)	41 (12.7)	5 (15.6)	0.020	3 (1.6)	<0.001
No	357 (85.2)	49 (75.4)	281 (87.3)	27 (84.4)	0.020	181 (98.4)	10.002
Household Contact of	337 (03.2)	13 (73.1)	201 (07.3)	27 (8 11 1)		101 (30.1)	
TB positive patient, No							
(%)							
Yes	159 (38.0)	27 (41.5)	119 (37.0)	13 (40.6)	0.754	_	_
No	256 (61.1)	38 (58.5)	199 (61.8)	19 (59.4)	0.754		-
Missing	4 (0.9)	0 (0.00)	4 (1.2)	0 (0.00)			
Smear Status, No (%)	4 (0.5)	0 (0.00)	4 (1.2)	0 (0.00)			
Positive	48 (11.5)	41 (63.1)	4 (1.2)	3 (9.4)	<0.001	0 (0.00)	<0.001
Negative	363 (86.6)	16 (24.6)	318 (98.8)	29 (90.6)	\0.001	183 (99.5)	\0.001
Missing	8 (1.9)	8 (12.3)	0 (0.00)	0 (0.00)		1 (0.5)	
IVIISSIIIB	0 (1.5)		iated Sympto			1 (0.5)	
Cough, No (%)		15 43300					
Length, in Weeks							
Less than 1 week	102 (24.4)	8 (12.3)	90 (28.0)	4 (12.5)	0.003	_	_
1-2 weeks	107 (25.5)	16 (24.6)	81 (25.1)	10 (31.2)			
More than 2 weeks	189 (45.1)	39 (60.0)	132 (41.0)	18 (56.3)			
Missing	21 (5.0)	2 (3.1)	19 (5.9)	0 (0.00)			
-				, ,			
Phlegm							
Yes	352 (84.0)	60 (92.3)	262 (81.4)	30 (93.8)	0.056	-	-
No	47 (11.2)	3 (4.6)	42 (13.0)	2 (6.2)			
Missing	20 (4.8)	2 (3.1)	18 (5.6)	0 (0.00)			
Blood							
Yes	166 (39.6)	33 (50.8)	120 (37.3)	13 (40.6)	0.068	_	_
	233 (55.6)	30 (46.2)	184 (57.1)	19 (59.4)	0.000		
No			1	0 (0.00)			
No Missing		2 (3 0)	X 5 h1				
Missing	20 (4.8)	2 (3.0)	18 (5.6)	0 (0.00)			
Missing Fever, No (%)	20 (4.8)				0.001	85 (46.2)	<0.001
Missing Fever, No (%) Yes	20 (4.8)	52 (80.0)	192 (59.6)	21 (65.6)	0.001	85 (46.2) 99 (53.8)	<0.001
Missing Fever, No (%)	20 (4.8)				0.001	85 (46.2) 99 (53.8) 0 (0)	<0.001

3 months, No (%)							
Yes	251 (59.9)	45 (69.2)	182 (56.5)	24 (75.0)	0.072	52 (28.3)	<0.001
No	168 (40.1)	20 (30.8)	140 (43.5)	8 (25.0)		132 (71.7)	
Weight Loss							
(unintentional), No (%)							
Yes	293 (69.9)	55 (84.6)	218 (67.7)	20 (62.5)	0.004	84 (45.6)	<0.001
No	123 (29.4)	9 (13.9)	102 (31.7)	12 (37.5)		98 (53.3)	
Refused	3 (0.7)	1 (1.5)	2 (0.6)	0 (0.00)		2 (1.1)	
Difficulty Breathing, No							
(%)							
Yes	335 (80.0)	51 (78.5)	260 (80.8)	24 (75.0)	0.732	52 (28.3)	<0.001
No	84 (20.0)	14 (21.5)	62 (19.2)	8 (25.0)		132 (71.7)	

[^] TB was diagnosed based on positive sputum culture i.e. pulmonary TB, we did not include clinical diagnoses or include evaluation for extra-pulmonary TB

Diagnostic accuracy

Using culture as the reference standard for pulmonary TB, qXR v4 (at the manufacturer pre-specified threshold of 0.65) had an overall sensitivity for pulmonary TB of 0.95 (62/65, 95% CI 0.87-0.99), specificity of 0.36 (116/322, 95% CI 0.31-0.42), and AUC of 0.66 (95% CI 0.62-0.69) (Table 2). Using Xpert as the reference standard for pulmonary TB, qXR v4 (at the manufacturer pre-specified threshold of 0.65) had an overall sensitivity of 0.93 (64/69, 95% CI 0.84-0.98), specificity of 0.36 (118/329, 95% CI 0.31-0.41), and AUC of 0.64 (95% CI 0.60-0.68) (Table 2). When the threshold was set such that sensitivity was 90% to match the WHO triage test accuracy performance criterion, specificity was 0.42 (135/322, 95% CI 0.37-0.48) and 0.42 (137/329, 95% CI 0.36-0.47) using the culture and Xpert reference standards respectively (Table 2).

^{*}Screening cohort consists of patients who did not report cough or TB risk factors

^{**}For continuous variables, an independent t-test was conducted. For binary variables, a Fisher's exact test was performed. For unordered categorical variables, Chi-square test was performed, and Jonckheere-Terpstra test was used for ordered categories. The first p value represents a comparison between participants with and without pulmonary TB in the triage cohort and the second p value represents the comparison between the overall triage and screening cohort participant groups. The missing and refused categories are excluded from statistical comparisons.

Table 2: Summary of Diagnostic Accuracy for qXR version 4 using the culture (primary) and Xpert (secondary) reference standards in the triage and screening cohorts.

		Triage Cohort		Sc	creening Cohort			
	(n=439)				(n= 191)			
	Sensitivity	Specificity	AUC	Sensitivity	Specificity	AUC		
	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)	(95% CI)		
			Culture					
Manufacturer	95.4%	36.0%	0.657	^	92.4%	=		
Threshold	62/65	116/322	(0.620,		159/172			
0.65	(87.1-99%)	(30.8-41.5%)	0.694)		(87.4 -95.6%)			
Threshold	90.8%	41.9%	0.663	^	95.3%	=		
0.788*	59/65	135/322	(0.619,		(164/172)			
	(81-96.5%)	(36.5-47.5%)	0.708)		(90.9-97.7%)			
			Xpert					
Manufacturer	92.8%	35.9%	0.643	100%	93.3%	0.966		
Threshold	64/69	118/329	(0.603,	1/1	167/179	(-, 1.00)		
0.65	(83.9-97.6%)	(30.7-41.3%)	0.683)	(2.5-100%)	(88.6-96.5%)			
Threshold	89.9%	41.6%	0.657	100%	96.1%	0.980		
0.79*	62/69	137/329	(0.613,	1/1	172/179	(-, 1.00)		
	(80.2-95.8%)	(36.3-47.2%)	0.702)	(2.5-100%)	(92.1-98.4%)			

^{*}threshold at which sensitivity is closest to 90%

There was no difference between the AUCs for qXR v4 and qXR v3 using either the culture reference standard (0.763 [95% CI 0.70-0.82] versus 0.780 [95% CI 0.72-0.84; p=0.438]) or the Xpert reference standard (0.748 [95% CI 0.69-0.81] versus 0.759 [95% CI 0.70-0.82]; p=0.611) (Figure 2).

Figure 2: Receiver operating characteristic (ROC) curves and estimates of area under the ROC curves (AUC) for qXR versions 3 and 4 to identify abnormalities consistent with TB in the triage cohort using the culture (left) and Xpert (right) reference standards.

[^]No positive cultures in the Screening Group

226

227

228

229230

231

232233234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

Stratified analyses There was no difference in qXR sensitivity (v4) when stratified by sex, age, prior TB, HIV, and symptoms (Figure 3). qXR specificity (v4) was higher in people without prior TB than in people with prior TB and with cough less than 2 weeks compared to cough for more than 2 weeks (Figure 4). Figure 3: Sensitivity of qXR version 4 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests. Figure 4: Specificity of qXR version 4 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests. Sensitivity analyses We examined qXR accuracy when pre-specified groups in whom TB diagnostic tests are often less sensitive (PWH, people with prior TB and people with other respiratory diseases) were excluded. Sensitivity for qXR v4 was slightly higher in people without HIV (0.98 [95% CI: 0.91-1.00]), people without prior TB (0.94 [95% CI: 0.84-0.99]), and people without other respiratory diseases (0.95 [95% CI: 0.87-0.99]). Specificity remained low in these groups (people without HIV: 0.34 [95% CI: 0.29-0.40], people without prior TB: 0.43 [95% CI: 0.36-0.50], and people without other respiratory diseases: 0.37 [95% CI: 0.31-0.43]) (Table S2). High prevalence of lung abnormalities A high prevalence of radiographic lung abnormalities, most notably opacities (82%), consolidation (63%), fibrosis (47%), nodules (57%), or cavitation (19%), was detected by qXR on digital CXR images from the triage cohort (Table S4).

Screening cohort

Compared to participants in the triage cohort, participants in the screening cohort were more likely to be younger and female, not have a history of HIV, any respiratory diseases or a prior history of TB, not have a history of incarceration, more likely to be non-smokers but more likely to report current alcohol use, and less likely to report fever, night sweats, or weight loss (Table 1). No participants in the screening cohort had a positive culture, and only one participant had a positive Xpert. Since there was only one person with confirmed TB in the screening group (who did have a qXR positive result), we only report specificity. Using the manufacturer's pre-specified thresholds, the specificity for qXR v4 was 0.92 (95% CI 0.87-0.96) using the culture reference standard and 0.95 (95% CI 0.91-0.98) using the Xpert reference standard (Table 2).

Discussion

In our study population of hospitalized patients at a tertiary referral hospital in Lima, Peru, the use of qXR artificial intelligence software analysis versions 3 and 4 in a triage cohort of patients with cough or TB risk factors demonstrated a high sensitivity (>90%) but low specificity (32-36%), thereby meeting only the WHO triage test criteria for sensitivity. In our screening cohort of patients without cough or risk factors, specificity was high (>90%) but sensitivity could not be evaluated since the diagnostic yield of screening this group in this setting was low (only one patient was diagnosed with Xpert-positive TB).

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

We previously reported that the FAST strategy using Xpert for molecular diagnosis increased the yield of TB diagnosis and decreased time to treatment initiation¹². Yet, despite WHO guidance that molecular WHO-recommended rapid TB diagnostic tests (mWRD) such as Xpert should be the initial test for people being evaluated for TB, implementation in Peru and other high-incidence settings has lagged¹. While barriers to mWRD implementation are multifactorial³⁶, cost and limited laboratory capacity were challenges to the implementation of Xpert as a triage or screening test as part of routine practice in our setting. The use of a triage tool such as digital CXR with CAD can help identify which patients should undergo testing with a mWRD¹⁶ as part of transmission prevention strategies such as FAST. In our hospitalized study population, qXR was highly sensitive for correctly triaging people identified as having cough or TB risk factors who had culture confirmed disease. Although low qXR specificity would lead to a large number of patients with false positive results who required confirmatory testing and widespread use of digital CXR with CAD poses implementation challenges, qXR as a triage tool could be of clinical and public health value due to its impact on diagnostic yield and may still save enough mWRDs to be cost-effective depending on the setting (cost-effectiveness analyses from our study are forthcoming). Our study adds further weight to the need for populationspecific thresholds³⁷ to optimize implementation of CAD tools in different settings.

The low specificity of qXR in inpatients with TB symptoms or risk factors contrasts with cross-sectional studies that found that qXR met WHO triage test criteria for both sensitivity (>90%) and specificity (70%) when evaluated in symptomatic outpatients in Bangladesh and Pakistan^{26,38}. Our triage cohort had a high prevalence of radiographic lung abnormalities, which was likely to be an important contributing factor to the lower than expected specificity in this cohort. Abnormal chest imaging findings in our study population may be due to inpatient populations in a tertiary referral

hospital being more likely to have acute illnesses such as pneumonia, and may also reflect a higher proportion of people with chronic lung disease in Lima, a city known to have high rates of air pollution, which has also been associated with a higher risk of tuberculosis³⁹.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Increasing data demonstrates symptom screening is insensitive⁴⁰ and often poorly implemented²⁴, and a high proportion of people with TB do not report symptoms²⁵. The inclusion of individuals without cough or risk factors in our screening cohort was designed to try to understand the potential diagnostic yield of using qXR as a screening tool to identify unsuspected TB in hospitalized patients who may be presenting for various other reasons. In this setting, the diagnostic yield of screening people without symptoms or risk factors was lower than expected (based on outpatient studies). The specificity of qXR was high, suggesting it could be a valuable rule-out test in this setting. The low prevalence of TB in the screening cohort may be an artifact of the sample size or, it may be because people with TB who present to hospital are more likely to be sicker due to TB and thus present with cough (resulting in exclusion from the screening cohort) compared to the outpatient populations in prevalence surveys. The exclusion of people with TB contacts and prior TB from the screening cohort may have also led to the screening cohort being a lower risk group. The implementation of strategies such as FAST should take into account local epidemiology--including the pre-test probability of TB in people who do not report symptoms—to determine the optimal approach to determining who should undergo mWRD testing. Other strategies could also be evaluated, to increase the sensitivity of screening.

Strengths of our study include generating CAD diagnostic accuracy data from inpatient populations, including those who were symptomatic and/or high-risk and those without identified cough or TB risk

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

factors, also contributing to a body of literature seeking to optimize the FAST facility-based transmission prevention strategy in a medium incidence setting. We provide the first head-to-head evaluation of version 4 (soon to be commercially available) compared to qXR version 3, and also characterize other lung abnormalities detected. Limitations of our study are that digital CXR could only be performed on inpatients admitted through the emergency room and that with only 65 patients who had culture-confirmed TB, the study only had sufficient power such that we can report the lower limit of the 95% CI for sensitivity is 0.885 with 95% precision. In conclusion, qXR had high sensitivity but low specificity as a triage tool in the context of use as part of the FAST strategy in hospitalized adults admitted to a tertiary referral hospital in Peru who had a high prevalence of other radiographic lung abnormalities. While specificity was high in patients without cough or risk factors, the diagnostic yield of screening these patients was low in this setting. These findings further support the need for population and setting-specific thresholds for CAD programs and provide additional insights into the role for triage testing in hospitalized patients, which remains critical to detect and treat individual patients earlier and to curb hospital TB transmission.

Supporting information captions:

Table S1: Summary of Culture and Xpert result concordance.

Table S2: Diagnostic accuracy of qXR Version 3 and 4 for pre-specified subgroups in the triage cohort for which participants with prior TB, respiratory diseases, and HIV, were excluded

Table S3: Summary of Diagnostic Accuracy for qXR version 4 compared to the culture (primary) and Xpert (secondary) reference standards

Table S4: Lung abnormalities detected by qXR analysis for the Triage and Screening cohorts

Figure S1: Sensitivity of qXR version 3 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests.

Figure S2: Specificity of qXR version 3 for culture-confirmed pulmonary tuberculosis, overall and in prespecified stratified groups. p values are from Fisher's exact tests.

Acknowledgements

The authors were allowed to use the qXR algorithms free of charge qure.ai for research purposes, but the companies had no influence over the research question, nor any other aspect of the work carried out, and had no impact on the transparency of the article.

Funding

This work was funded by the National Institutes of Health (NIAID R01 AI112748, PIs: Nardell and Tierney, and NIAID K23 AI132648-05, PI: Nathavitharana). RRN also acknowledges support from an American Society of Tropical Medicine and Hygiene Burroughs Wellcome Fellowship.

The funders had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication. The content is solely the responsibility of the authors and does not necessarily represent the views of the funders.

Competing interests

The authors declare that no competing interests exist.

Data Availability Statement

All relevant data are uploaded to the Harvard Dataverse repository.


References

- 1. World Health Organization. *Global Tuberculosis Report 2022*. World Health Organization; 2022. Accessed December 5, 2022. https://apps.who.int/iris/handle/10665/363752
- 2. Subbaraman R, Jhaveri T, Nathavitharana RR. Closing gaps in the tuberculosis care cascade: an action-oriented research agenda. *J Clin Tuberc Other Mycobact Dis*. 2020;19:100144. doi:10.1016/j.jctube.2020.100144
- 3. Willingham FF, Schmitz TL, Contreras M, et al. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. *Emerg Infect Dis.* 2001;7(1):123-127. doi:10.3201/eid0701.010117
- 4. Assefa D, Belachew F, Wondimagegn G, Klinkenberg E. Missed pulmonary tuberculosis: a cross sectional study in the general medical inpatient wards of a large referral hospital in Ethiopia. *BMC Infect Dis.* 2019;19(1):60. doi:10.1186/s12879-019-3716-x
- 5. Gandhi NR, Weissman D, Moodley P, et al. Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. *J Infect Dis*. 2013;207(1):9-17. doi:10.1093/infdis/jis631
- 6. Migliori GB, Nardell E, Yedilbayev A, et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. *Eur Respir J*. 2019;53(6). doi:10.1183/13993003.00391-2019
- 7. Nardell EA. Transmission and Institutional Infection Control of Tuberculosis. *Cold Spring Harb Perspect Med*. 2015;6(2):a018192. doi:10.1101/cshperspect.a018192
- 8. World Health Organization. *Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis*. World Health Organization; 2022:6. Accessed June 6, 2022. https://apps.who.int/iris/handle/10665/353743
- 9. Paleckyte A, Dissanayake O, Mpagama S, Lipman MC, McHugh TD. Reducing the risk of tuberculosis transmission for HCWs in high incidence settings. *Antimicrob Resist Infect Control*. 2021;10(1):106. doi:10.1186/s13756-021-00975-y
- 10. Barrera E, Livchits V, Nardell E. F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy. *Int J Tuberc Lung Dis.* 2015;19(4):381-384. doi:10.5588/ijtld.14.0680
- 11. Tierney DB, Orvis E, Nathavitharana RR, et al. FAST tuberculosis transmission control strategy speeds the start of tuberculosis treatment at a general hospital in Lima, Peru. *Infect Control Hosp Epidemiol*. Published online October 6, 2021:1-7. doi:10.1017/ice.2021.422

- 12. Nathavitharana RR, Daru P, Barrera AE, et al. FAST implementation in Bangladesh: high frequency of unsuspected tuberculosis justifies challenges of scale-up. *Int J Tuberc Lung Dis*. 2017;21(9):1020-1025. doi:10.5588/ijtld.16.0794
- 13. Miller AC, Livchits V, Ahmad Khan F, et al. Turning Off the Tap: Using the FAST Approach to Stop the Spread of Drug-Resistant Tuberculosis in the Russian Federation. *The Journal of Infectious Diseases*. 2018;218(4):654-658. doi:10.1093/infdis/jiy190
- 14. Le H, Nguyen N, Tran P, et al. Process measure of FAST tuberculosis infection control demonstrates delay in likely effective treatment. *Int J Tuberc Lung Dis*. 2019;23(2):140-146. doi:10.5588/ijtld.18.0268
- 15. WHO. WHO Consolidated guidelines on tuberculosis, Module 2: Screening, Systematic screening for tuberculosis disease. Published online 2021. https://reliefweb.int/report/world/who-consolidated-guidelines-tuberculosis-module-2-screening-systematic-screening
- 16. Nathavitharana RR, Yoon C, Macpherson P, et al. Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. *The Journal of Infectious Diseases*. 2019;220(Supplement_3):S116-S125. doi:10.1093/infdis/jiz243
- 17. WHO. CHEST RADIOGRAPHY IN TUBERCULOSIS DETECTION. Published online 2016. https://apps.who.int/iris/bitstream/handle/10665/252424/9789241511506-eng.pdf
- 18. Kik SV, Gelaw SM, Ruhwald M, et al. *Diagnostic Accuracy of Chest X-Ray Interpretation for Tuberculosis by Three Artificial Intelligence-Based Software in a Screening Use-Case: An Individual Patient Meta-Analysis of Global Data*. Infectious Diseases (except HIV/AIDS); 2022. doi:10.1101/2022.01.24.22269730
- 19. Gelaw SM, Kik SV, Ruhwald M, et al. *Diagnostic Accuracy of Three Computer-Aided Detection Systems for Detecting Pulmonary Tuberculosis on Chest Radiography When Used for Screening: Analysis of an International, Multicenter Migrants Screening Study*. Radiology and Imaging; 2022. doi:10.1101/2022.03.30.22273191
- 20. Qin ZZ, Mthiyane T, Barrett R, Moyo S, Zuma K, Manda S. Head-to-head evaluation of computer automated reading software to detect tuberculosis-related abnormalities from chest x-ray images using South Africa prevalence survey results. *Unpublished*.
- 21. Qin ZZ, Mhe SA, Sarker MS, et al. Can artificial intelligence (AI) be used to accurately detect tuberculosis (TB) from chest X-rays? An evaluation of five AI products for TB triaging in a high TB burden setting. :46.
- 22. Tavaziva G, Harris M, Abidi SK, et al. Chest X-ray Analysis With Deep Learning-Based Software as a Triage Test for Pulmonary Tuberculosis: An Individual Patient Data Meta-Analysis of Diagnostic Accuracy. *Clinical Infectious Diseases*. Published online July 21, 2021:ciab639. doi:10.1093/cid/ciab639

- 23. Nash M, Kadavigere R, Andrade J, et al. Deep learning, computer-aided radiography reading for tuberculosis: a diagnostic accuracy study from a tertiary hospital in India. *Sci Rep.* 2020;10(1):210. doi:10.1038/s41598-019-56589-3
- 24. Divala TH, Lewis J, Bulterys MA, Lutje V, Corbett EL, Schumacher SG. Missed opportunities for diagnosis and treatment in patients with TB symptoms: a systematic review. *Public Health Action*.:8.
- 25. Frascella B, Richards AS, Sossen B, et al. Subclinical Tuberculosis Disease—A Review and Analysis of Prevalence Surveys to Inform Definitions, Burden, Associations, and Screening Methodology. *Clinical Infectious Diseases*. 2021;73(3):e830-e841. doi:10.1093/cid/ciaa1402
- 26. Qin ZZ, Ahmed S, Sarker MS, et al. Tuberculosis detection from chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial intelligence algorithms. *The Lancet Digital Health*. 2021;3(9):e543-e554. doi:10.1016/S2589-7500(21)00116-3
- 27. Muyoyeta M, Maduskar P, Moyo M, et al. The Sensitivity and Specificity of Using a Computer Aided Diagnosis Program for Automatically Scoring Chest X-Rays of Presumptive TB Patients Compared with Xpert MTB/RIF in Lusaka Zambia. Wilkinson RJ, ed. *PLoS ONE*. 2014;9(4):e93757. doi:10.1371/journal.pone.0093757
- 28. Breuninger M, van Ginneken B, Philipsen RHHM, et al. Diagnostic Accuracy of Computer-Aided Detection of Pulmonary Tuberculosis in Chest Radiographs: A Validation Study from Sub-Saharan Africa. Hoshino Y, ed. *PLoS ONE*. 2014;9(9):e106381. doi:10.1371/journal.pone.0106381
- 29. Melendez J, Sánchez CI, Philipsen RHHM, et al. An automated tuberculosis screening strategy combining X-ray-based computer-aided detection and clinical information. *Sci Rep*. 2016;6(1):25265. doi:10.1038/srep25265
- 30. Yuen CM, Puma D, Millones AK, et al. Identifying barriers and facilitators to implementation of community-based tuberculosis active case finding with mobile X-ray units in Lima, Peru: a RE-AIM evaluation. *BMJ Open*. 2021;11(7):e050314. doi:10.1136/bmjopen-2021-050314
- 31. Nguyen LH, Codlin AJ, Vo LNQ, et al. An Evaluation of Programmatic Community-Based Chest X-ray Screening for Tuberculosis in Ho Chi Minh City, Vietnam. *TropicalMed*. 2020;5(4):185. doi:10.3390/tropicalmed5040185
- 32. Madhani F, Maniar RA, Burfat A, et al. Automated chest radiography and mass systematic screening for tuberculosis. *int j tuberc lung dis*. 2020;24(7):665-673. doi:10.5588/ijtld.19.0501
- 33. Mungai B, Ongʻangò J, Ku CC, et al. Accuracy of computer-aided chest X-ray in community-based tuberculosis screening: Lessons from the 2016 Kenya National Tuberculosis Prevalence Survey. Majumdar S, ed. *PLOS Glob Public Health*. 2022;2(11):e0001272. doi:10.1371/journal.pgph.0001272

- 34. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*. Published online October 28, 2015:h5527. doi:10.1136/bmj.h5527
- 35. World Health Organization. *High-Priority Target Product Profi Les for New Tuberculosis Diagnostics: Report of a Consensus Meeting.*; 2014.
- 36. Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? *Eur Respir J.* 2016;48(2):516-525. doi:10.1183/13993003.00543-2016
- 37. Qin ZZ, Sander MS, Rai B, et al. Using artificial intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of the diagnostic accuracy of three deep learning systems. *Sci Rep.* 2019;9(1):15000. doi:10.1038/s41598-019-51503-3
- 38. Khan FA, Majidulla A, Tavaziva G, et al. Chest x-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: a prospective study of diagnostic accuracy for culture-confirmed disease. *The Lancet Digital Health*. 2020;2(11):e573-e581. doi:10.1016/S2589-7500(20)30221-1
- 39. Lin YJ, Lin HC, Yang YF, et al. Association Between Ambient Air Pollution and Elevated Risk of Tuberculosis Development. *IDR*. 2019;Volume 12:3835-3847. doi:10.2147/IDR.S227823
- 40. Yoon C, Dowdy DW, Esmail H, MacPherson P, Schumacher SG. Screening for tuberculosis: time to move beyond symptoms. *The Lancet Respiratory Medicine*. 2019;7(3):202-204. doi:10.1016/S2213-2600(19)30039-6
- 41. Mungai BN, Joekes E, Masini E, et al. 'If not TB, what could it be?' Chest X-ray findings from the 2016 Kenya Tuberculosis Prevalence Survey. *Thorax*. 2021;76(6):607-614. doi:10.1136/thoraxjnl-2020-216123
- 42. Engle E, Gabrielian A, Long A, Hurt DE, Rosenthal A. Performance of Qure.ai automatic classifiers against a large annotated database of patients with diverse forms of tuberculosis. Hong JC, ed. *PLoS ONE*. 2020;15(1):e0224445. doi:10.1371/journal.pone.0224445
- 43. Singh R, Kalra MK, Nitiwarangkul C, et al. Deep learning in chest radiography: Detection of findings and presence of change. Eapen GA, ed. *PLoS ONE*. 2018;13(10):e0204155. doi:10.1371/journal.pone.0204155



Category and Variable	nN	p-value		Specificity (95% CI)
Demographics				
Male	48/188	0.052		0.26 (0.20, 0.32)
Female	54/134			0.40 (0.32, 0.49)
<40 years	51/150	0.571		0.34 (0.27, 0.42)
>40 years	51/172		→	0.30 (0.23, 0.37)
Risk Factors				
No Prior TB	84/207	0.001		0.41 (0.34, 0.48)
Prior TB	18/114			0.16 (0.10, 0.24)
HIV Negative	89/294	0.095	→	0.30 (0.25, 0.36)
HIV Positive	15/28			0.46 (0.28, 0.66)
Clinical Symptoms				
Cough > 2 weeks	26/132	0.006		0.20 (0.13, 0.28)
Cough < 2 weeks	69/171			0.40 (0.33, 0.48)
Night sweats	55/182	0.649	→	0.30 (0.24, 0.38)
No Night sweats	47/140		—	0.34 (0.26, 0.42)
Fever	58/192	0.645		0.30 (0.24, 0.37)
No Fever	44/130		—	0.34 (0.26, 0.43)
Weight Loss	55/218	0.012		0.25 (0.20, 0.32)
No Weight Loss	47/102			0.46 (0.36, 0.56)
Overall				
Overall	102/322		→	0.32 (0.27, 0.37)
		0	.2 .4 .6 .8	1 8 1

madR&v preprint@iDipe://doi.org/10.1101/2023.05.11 (which was not certified by peer review) is the auth It is made available	7.23290110; this version posted May or/funder, who has granted medRxiv ble under a CC-BY 4.0 International I	24, 2028 The coeyright holder for this prepring a license to display the preprint in perpetuity. icense.	Sensitiv (95% C	•
Demographics				
Male	44/48	1.000	→ 0.92 (0.	80, 0.98)
Female	15/17		── 0.88 (0.	64, 0.98)
<40 years	35/38	1.000	─ 0.92 (0.	79, 0.98)
>40 years	24/27		0.89 (0.	71, 0.98)
Risk Factors				
No Prior TB	46/52	0.828	─ 0.89 (0.	77, 0.96)
Prior TB	13/13		── 1.00 (0.	75, 1.00)
HIV Negative	54/58	0.766	→ 0.93 (0.	83, 0.98)
HIV Positive	5/7	_	0.71 (0.	29, 0.96)
Clinical Symptoms				
Cough > 2 weeks	37/39	0.850	→ 0.95 (0.	83, 0.99)
Cough < 2 weeks	20/24		0.83 (0.	63, 0.95)
Night sweats	39/45	0.848	0.87 (0.	73, 0.95)
No Night sweats	20/20		→ 1.00 (0.	83, 1.00)
Fever	46/52	0.823	─ 0.89 (0.	77, 0.96)
No Fever	12/12		1.00 (0.	73, 1.00)
Weight Loss	49/55	1.000	0.89 (0.	78, 0.96)
No Weight Loss	9/9		── 1.00 (0.	66, 1.00)
Test Results				
Smear Positive	38/41	0.830	─ 0.93 (0.	80, 0.98)
Smear Negative	13/16		0.81 (0.	54, 0.96)
Overall				
Overall	59/65		→ 0.91 (0.	81, 0.96)
		1 1		
		0 .2 .	4 .6 .8 1	

medRxiv preprint doi: https://doi.org/10.1101/2023.05.17. (which was not certified by peer review) is the author. It is made available	23290110; this version posted May /funder, who has granted medRxiv e under a CC-BY 4.0 International I	24, 2023 The copyright holder for a license to display the preprint in picense.	Sensitivity this preprint (95% CI)
Demographics			
Male	46/48	1.000	→ 0.96 (0.86, 0.99)
Female	16/17		→ 0.94 (0.71, 1.00)
<40 years	37/38	1.000	→ 0.97 (0.86, 1.00)
>40 years	25/27		0.93 (0.76, 0.99)
Risk Factors			
No Prior TB	49/52	1.000	→ 0.94 (0.84, 0.99)
Prior TB	13/13		1.00 (0.75, 1.00)
HIV Negative	57/58	0.764	→ 0.98 (0.91, 1.00)
HIV Positive	5/7		0.71 (0.29, 0.96)
Clinical Symptoms			
Cough > 2 weeks	37/39	1.000	─ 0.95 (0.83, 0.99)
Cough < 2 weeks	23/24		→ 0.96 (0.79, 1.00)
Night sweats	42/45	1.000	0.93 (0.82, 0.99)
No Night sweats	20/20		→ 1.00 (0.83, 1.00)
Fever	49/52	1.000	→ 0.94 (0.84, 0.99)
No Fever	12/12		── 1.00 (0.73, 1.00)
Weight Loss	52/55	1.000	→ 0.94 (0.85, 0.99)
No Weight Loss	9/9		→ 1.00 (0.66, 1.00)
Test Results			
Smear Positive	40/41	0.833	→ 0.98 (0.87, 1.00)
Smear Negative	14/16		0.88 (0.62, 0.98)
Overall			
Overall	62/65		→ 0.95 (0.87, 0.99)
		1 1	1 1 1 1

Category and Variable	nN	p-value		Specificity (95% CI)
Demographics				
Male	56/188	0.065		0.30 (0.23, 0.37)
Female	60/134	0.000	-	0.45 (0.36, 0.54)
<40 years	59/150	0.449	-	0.39 (0.32, 0.48)
>40 years	57/172	00	→	0.33 (0.26, 0.41)
Risk Factors				
No Prior TB	89/207	0.015	→	0.43 (0.36, 0.50)
Prior TB	27/114		→	0.24 (0.16, 0.33)
HIV Negative	101/294	0.204	-	0.34 (0.29, 0.40)
HIV Positive	13/22			0.54 (0.34, 0.72)
Clinical Symptoms				
Cough > 2 weeks	26/132	0.001	→	0.20 (0.13, 0.28)
Cough < 2 weeks	79/171			0.46 (0.39, 0.54)
Night sweats	62/182	0.587	→	0.34 (0.27, 0.41)
No Night sweats	54/140		—	0.39 (0.30, 0.47)
Fever	63/192	0.325	→	0.33 (0.26, 0.40)
No Fever	53/130		—	0.41 (0.32, 0.50)
Weight Loss	68/218	0.069		0.31 (0.25, 0.38)
No Weight Loss	48/102		—	0.47 (0.37, 0.57)
Overall				
Overall	116/322			0.36 (0.31, 0.41)
				ı

0 .2 .4 .6 .8 1

